Key Insights

Highlights

Success Rate

81% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

13.0%

3 terminated out of 23 trials

Success Rate

81.3%

-5.3% vs benchmark

Late-Stage Pipeline

13%

3 trials in Phase 3/4

Results Transparency

46%

6 of 13 completed with results

Key Signals

6 with results81% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (4)
Early P 1 (3)
P 1 (5)
P 2 (7)
P 3 (3)

Trial Status

Completed13
Recruiting3
Terminated3
Unknown1
Active Not Recruiting1
Not Yet Recruiting1

Trial Success Rate

81.3%

Benchmark: 86.5%

Based on 13 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT06015737Phase 3Active Not RecruitingPrimary

A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus

NCT06661213Early Phase 1Enrolling By InvitationPrimary

Tapinarof for Cutaneous Lupus Erythematosus

NCT07355218Phase 3Recruiting

A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease (ELOWEN-2)

NCT07408908Phase 1Not Yet Recruiting

Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic (PK/PD) Profile of ACT100 in Healthy Participants..

NCT04781816Phase 2CompletedPrimary

Proof of Concept Study of SAR443122 in Patients With Cutaneous Lupus Erythematosus

NCT07072611Early Phase 1RecruitingPrimary

Clinical Trial to Evaluate Safety, Tolerability, and Pharmacokinetics of SOF-SKN in Healthy Participants

NCT03817424Phase 1Completed

A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis

NCT06411106Not ApplicableRecruitingPrimary

Deep Phenotyping of Cutaneous Lupus Erythematosus

NCT04809623Phase 1TerminatedPrimary

Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

NCT04647708Phase 1Completed

Study of M5049 in CLE and SLE Participants

NCT01776190Not ApplicableCompletedPrimary

Low-dose UVA1 Radiation in Cutaneous Lupus Patients

NCT03260166Phase 2UnknownPrimary

Nicotinamide Treatment for Lupus-associated Skin Lesions in Lupus Erythematosus

NCT01300208Phase 2CompletedPrimary

To Evaluate the Preliminary Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CC-11050 in Subjects With Discoid Lupus Erythematosus and Subacute Cutaneous Lupus Erythematosus

NCT03134222Phase 2CompletedPrimary

Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE)

NCT01146444Not ApplicableCompletedPrimary

Sunscreens in Patients With Cutaneous Lupus Erythematosus(CLE)

NCT01841619Early Phase 1CompletedPrimary

IVIg Efficacy Study to Treat Cutaneous Lupus Erythematosus

NCT01470313Phase 1TerminatedPrimary

A Multiple Dose Study Of PD-0360324 In Patients With Active Cutaneous Lupus Erythematosus

NCT00420173CompletedPrimary

Interdisciplinary Study Group of Lupus Erythematosus (ISGLE)

NCT01498406Phase 2TerminatedPrimary

Vitamin D Status, Disease Specific and Quality of Life Outcomes in Patients With Cutaneous Lupus

NCT01629784Not ApplicableCompletedPrimary

Effectiveness of a Knowledge-based Intervention for Patients With Cutaneous Lupus Erythematosus

Scroll to load more

Research Network

Activity Timeline